BOT Botanix Pharmaceuticals Ltd
- 0.420
- +0.025+6.33%
Botanix Pharmaceuticals Ltd News
Those Who Invested in Botanix Pharmaceuticals (ASX:BOT) Three Years Ago Are up 443%
Botanix Pharmaceuticals Says US Payer Group to Cover Its Excessive Sweat Medication; Shares Up 6%
Botanix Pharmaceuticals on Track to Launch Patient Experience Program for Sofdra in Q4; Shares Up 6%
Here's Why We're Not At All Concerned With Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation
Breakeven Is Near for Botanix Pharmaceuticals Limited (ASX:BOT)
Botanix Pharmaceuticals Ltd: Annual Report
Botanix Pharmaceuticals' Revenue Climbs in Fiscal 2024, Loss Per Share Widens; Shares Up 9%
Botanix Pharmaceuticals Ltd: Botanix Appendix 4E & Announcement of Commercial Day Webinar
2 Promising Small-cap ASX Healthcare Stocks to Buy Now
2 ASX Healthcare Shares Making Splashes in the US
Euroz Hartleys Upgrades Botanix Pharmaceuticals' to Buy From Speculative Buy, Adjusts Price Target to AU$0.47 From AU$0.33
Botanix Pharmaceuticals to Raise AU$70 Million via Institutional Placement
Botanix Pharmaceuticals Secures US FDA Approval for Topical Medication
Botanix Pharmaceuticals Share Price on Watch Amid FDA News and 'Transformative Event'
Botanix Isn't Sweating on FDA Approval for Sofdra
Botanix Pharmaceuticals Submits Last Label Materials for Sofdra FDA Approval
Evans & Partners Starts Botanix Pharmaceuticals at Speculative Buy With AU$0.55 Price Target
Euroz Hartleys Adjusts Botanix Pharmaceutical's Price Target to AU$0.33 From AU$0.30, Keeps at Speculative Buy
Botanix Pharmaceuticals Price Target Raised 10% to A$0.33/Share by Euroz Hartleys
We're Keeping An Eye On Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Rate
No Data